Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A six-month head-to-head superiority clinical study of SEL-212 compared to Krystexxa

Trial Profile

A six-month head-to-head superiority clinical study of SEL-212 compared to Krystexxa

Planning
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs SEL 212 (Primary) ; Pegloticase
  • Indications Gout
  • Focus Therapeutic Use
  • Sponsors Selecta Biosciences
  • Most Recent Events

    • 03 Jan 2019 According to a Selecta Biosciences media release, of an interim six-month data readout is projected for the fourth quarter 2019 with a full statistical superiority data analysis expected in the first quarter of 2020.
    • 08 Nov 2018 According to a Selecta Biosciences media release, the company expects to start this study in the first quarter of 2019, with interim data readouts expected in 2019 and full data presentation anticipated in first quarter of 2020.
    • 27 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top